跳至主要内容
临床试验/NCT03453424
NCT03453424已完成2 期

Analgesic Efficacy of Dexmedetomidine Added to Patient Controlled Epidural Analgesia for Patients Undergoing Major Abdominal Cancer Surgery

South Egypt Cancer Institute1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2017年6月30日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
90
试验地点
1
主要终点
Change in pain scores (dynamic VAS)

研究概览

简要总结

Dexmedetomidine if add to patient controlled epidural analgesia for patients undergoing major abdominal cancer surgery may improve its effects.

详细描述

The aim of modern anaesthetic practice is to insure the rapid recovery of patients with fewer complications and earlier hospital discharge.

Thoracic epidural anesthesia (TEA) has been established as a cornerstone in the perioperative care after thoracic and major abdominal surgery providing most effective analgesia. beyond its analgesic properties, TEA's effects on the postoperative neurohumoural stress response, cardiovascular Pathophysiology, and intestinal dysfunction have been in the focus of both clinical and experimental investigations for years.

dexmedetomidine if add to patient controlled epidural analgesia for patients undergoing major abdominal cancer surgery may improve its effects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • adult patients (21 years old or more),
  • classified as American Society of Anesthesiologists (ASA) grade II and III,
  • scheduled for elective major abdominal cancer surgery.

排除标准

  • patients with coagulopathy,
  • active neurological disease,
  • cutaneous disorders at the epidural insertion site,
  • allergy to the study medication
  • and patients refusal.

结局指标

主要结局

Change in pain scores (dynamic VAS)

时间窗: at 0, 4, 8, 12, 18, 24, 36 and 48 hours post operative.

dynamic visual analogue scale (0-10) 0=no pain 10=worst imaginable pain

次要结局

  • Change in post operative MAP(at 0, 4, 8, 12, 18, 24, 36 and 48 hours post operative.)

研究者

发起方
South Egypt Cancer Institute
申办方类型
Other
责任方
Principal Investigator
主要研究者

Alaa Ali M. Elzohry

Principal Investigator

South Egypt Cancer Institute

研究点 (1)

Loading locations...

相似试验